Combining RapiFluor-MS and UNIFI Scientific Information System for a Total N-linked Glycan Solution for Innovator vs. Biosimilar Infliximab Comparisons

Applications | 2016 | WatersInstrumentation
LC/TOF, LC/HRMS, LC/MS, LC/MS/MS
Industries
Pharma & Biopharma
Manufacturer
Waters

Significance of the topic


Glycosylation of monoclonal antibodies plays a critical role in therapeutic function, including antibody-dependent cellular cytotoxicity and pharmacokinetics. As patents expire on innovator mAbs, biosimilar development demands rigorous glycan profiling to ensure structural and functional equivalence.

Objectives and Study Overview


This study presents a streamlined, end-to-end N-linked glycan analysis workflow combining fast sample preparation, high-resolution LC-FLR-MS analysis, and automated data processing. Innovator infliximab (Remicade®) and a biosimilar (Inflectra®) were compared to evaluate the method’s capability for biosimilarity assessment.

Methodology


Sample preparation was performed in under one hour using the GlycoWorks RapiFluor-MS N-Glycan Kit: mAb denaturation, rapid PNGase F release, RFMS labeling in glycosylaminyl form, followed by HILIC μ-elution cleanup. Chromatography used an ACQUITY UPLC Glycan BEH Amide column (2.1×150 mm, 1.7 μm) at 60 °C with a gradient of ammonium formate (pH 4.4) and acetonitrile. Fluorescence detection was set at Ex 265 nm/Em 425 nm. Mass spectrometry employed a Xevo G2-XS QTof in positive mode with lockmass calibration (Glu-Fibrinopeptide B). Data acquisition and processing utilized UNIFI Scientific Information System with GU calibration via a dextran ladder, automated library searches (ΔGU 0.2), comparative analysis tools, and customizable reporting.

Used Instrumentation

  • GlycoWorks RapiFluor-MS N-Glycan Kit
  • ACQUITY UPLC H-Class Bio System with Glycan BEH Amide column
  • Xevo G2-XS QTof Mass Spectrometer
  • UNIFI Scientific Information System with Glycan Application Solution and GU library

Main Results and Discussion


Retention times were normalized to glucose units, minimizing inter-run variability. Library searching identified 23 mass-confirmed glycans in Remicade® and 22 in Inflectra®. Stacked FLR chromatograms showed high qualitative similarity, while difference plots revealed slight increases in NeuGc-terminated species and specific antennary galactosylated structures in the biosimilar. Quantitative summary plots (% amount) confirmed these trends with RSDs < 1%, demonstrating robust reproducibility.

Benefits and Practical Applications


This total workflow accelerates glycan profiling with less than one-hour sample prep and enhanced detection of low-abundance and sialylated species. Automated GU calibration and library searches enable non-specialists to perform detailed glycan analysis, supporting QA/QC in biosimilar development, bioprocess monitoring, and regulatory comparability studies.

Future Trends and Potential Applications


Future developments include expansion of comprehensive RFMS-labeled glycan GU libraries, integration of deeper structural elucidation tools, automated high-throughput workflows, and application to a wider range of biotherapeutics, including fusion proteins and complex glycoproteins. Machine-learning based spectral interpretation may further enhance glycan identification and quantitation.

Conclusion


The combined RapiFluor-MS, UPLC H-Class Bio, Xevo G2-XS QTof, and UNIFI platform provides a robust, rapid, and user-friendly solution for N-linked glycan analysis. It streamlines sample prep, improves sensitivity, and offers automated data processing and reporting, facilitating accurate biosimilar comparability and accelerating biopharmaceutical development.

References

  1. Shields R.L.; Lai J.; Keck R.; et al. J. Biol. Chem. 2002;277:26733–26740.
  2. Lauber M.A.; Yu Y.Q.; Brousmiche D.W.; et al. Anal. Chem. 2015;87:5401–5409.
  3. Guile G.R.; Rudd P.M.; Wing D.R.; Prime S.B.; Dwek R.A. Anal. Biochem. 1996;240:210–226.
  4. Yu Y.Q. Waters Application Note 720004845EN. 2013.
  5. Waters GlycoWorks RapiFluor-MS N-Glycan Kit User Manual 715004793EN. 2016.
  6. Campbell M.P.; Royle L.; Radcliffe C.M.; Dwek R.A.; Rudd P.M. Bioinformatics. 2008;24:1214–1216.
  7. Jung S.K.; Lee K.H.; Jeon J.W.; et al. MAbs. 2014;6:1163–1177.

Content was automatically generated from an orignal PDF document using AI and may contain inaccuracies.

Downloadable PDF for viewing
 

Similar PDF

Increasing Productivity and Confidence for N-linked Glycan Analysis of Biosimilars Using the BioAccord System
Characterization of Released N-linked Glycans in Biosimilar mAb Drug Products Using the Xevo™ G3 QTof
BIOPHARMACEUTICAL - Key Applications
Waters Application Notes - Glycans